An article in Food and Drug Law Institute Update by life sciences regulatory & compliance partner Joshua Oyster and associates Rebecca Williams and Helen Ryan (all of Washington, D.C.), reviewed the impact of COVID-19 on the U.S. Food and Drug Administration’s ability to monitor and enforce current good manufacturing practice compliance (CGMP) and analyzed the resulting shift in manufacturing-related warning letters based on FDA’s alternative tools and other recent trends.
The authors conclude that FDA’s use of sample testing and records requests has been integral to the agency’s efforts to ensure continued CGMP compliance and product quality during a time when the agency’s ability to conduct inspections has been limited.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find our more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.